Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases

Aim. To perform health-economic evaluation of trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis and budget impact analysis were performed. Direct medical costs and indirect costs (...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. S. Kolbin, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, D. R. Naskhletashvili
Formato:	Artigo
Idioma:	Russo
Publicado em:	Izdatelstvo OKI 2018-05-01
coleção:	Качественная клиническая практика
Assuntos:	рак молочной железы трастузумаб эмтазин анализ эффективности затрат фармакоэкономика breast cancer trastuzumab emtanzine caost-effectiveness analysis health-economics
Acesso em linha:	https://www.clinvest.ru/jour/article/view/82
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!